Effect evaluation method and system of chicken mycoplasma synoviae inactivated vaccine
By setting up animal experimental groups and control groups of different types and production cycles, combining multiple detection methods and statistical analysis, the problem of sample size optimization in traditional vaccine evaluation is solved, and the accurate evaluation and safety assessment of vaccine effect is achieved. Scientific and objective evaluation results.
Patent Information
- Application Number
- CN202411045464.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
In the evaluation of the effect of the traditional chicken sacrum mycoplasma inactivated vaccine, the control test sample size cannot be optimized according to the different types of animals and the production age group, which makes it difficult to achieve data accuracy and statistical effects.
Animal experimental groups and control groups with different types and production cycles were established, and data were collected and analyzed through various detection methods (such as ELISA, qPCR, pathological examination), sample size was calculated in combination with statistical methods, and data cleaning was designed. Classify and standardize the treatment, and finally conduct vaccine effectiveness and safety assessment.
A comprehensive assessment of the effectiveness and safety of vaccine immune protection is achieved, ensuring the accuracy and reliability of the evaluation results, and is suitable for a variety of laboratory and field environments.
Smart Images

Figure CN118980814A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of vaccine evaluation, and in particular to an effect evaluation method and system for an inactivated Mycoplasma synoviae vaccine. Background Art
[0002] Mycoplasma synoviae (MS), also known as infectious synovitis, is an acute or chronic infectious disease of chickens and turkeys caused by Mycoplasma synoviae. Infectious synovitis was first reported by Olson et al. (1964). The disease mainly attacks the synovial fluid and tendon sheath of the joints, and is characterized by swelling of the joints, tendon sheaths and soles of the feet. Infection of chickens with the disease can lead to obvious lameness, growth retardation and carcass downgrading. The disease can be transmitted vertically, causing illness in chicks hatched from eggs laid by breeder hens during the onset of the disease. Infection with Mycoplasma synoviae has spread throughout the world and is distributed worldwide. It mainly attacks commercial broilers, laying hens and breeder hens. The disease can occur all year round, but is more prone to occur in winter and spring.
[0003] When conducting experiments on traditional chicken synoviae Mycoplasma inactivated vaccines, it is necessary to conduct control experiments in combination with multiple biological control groups and experimental groups to ensure the accuracy of various data during the experiment. However, the existing control experiments cannot be optimized according to animal characteristics during implementation. For example, the control experiments on animals of different types and different production age groups result in a lack of control experiment sample size, making it impossible to effectively calculate the control experiment results. Summary of the invention
[0004] The object of the present invention is to provide a method and system for evaluating the effect of an inactivated Mycoplasma synoviae vaccine to solve the problems raised in the above-mentioned background technology.
[0005] To achieve the above object, the present invention provides the following technical solution: a method for evaluating the effect of an inactivated vaccine of Mycoplasma synoviae, comprising the following steps:
[0006] S1. Set up animal experimental group and control group. The experimental group will be vaccinated with inactivated vaccine, while the control group will not be vaccinated. The experimental group and control group will be divided into groups of animals of different types and production cycles. Then, animal samples will be collected, including blood, synovial fluid and tissue samples, and then clinical symptoms will be monitored.
[0007] S2. Test animal samples, measure serum antibody levels by ELISA or microneutralization test, detect pathogen load by qPCR or real-time quantitative PCR, and then observe pathological changes of synovial bursa by tissue section pathological examination;
[0008] S3. On-site data collection, including vaccination records and production performance index records. Vaccination records include vaccination dose, vaccination time, vaccination site, and production performance indicators such as weight gain, feed conversion rate, and egg production rate of laying hens;
[0009] S4. Process the data, including removing outliers and erroneous data to clean the data, classifying the data by experimental group, control group, time point, and test item, and standardizing the data to eliminate differences between different experiments;
[0010] S5. Data analysis and processing, including antibody titer analysis, pathogen load analysis, clinical symptom scoring, and pathological analysis;
[0011] S6. The effects are then evaluated, including vaccine effectiveness evaluation, comprehensive evaluation of the vaccine's immune protection effect through antibody titer, pathogen load, clinical symptom score, calculation of protection rate and relative protection rate, vaccine safety evaluation, evaluation of the incidence and severity of adverse reactions after vaccination, analysis of changes in production performance indicators, and evaluation of the impact of the vaccine on production performance.
[0012] Preferably, the antibody titer analysis: calculating the geometric mean and standard deviation of the antibody titer, and using t-test and MannWhitneyU test to compare the difference in antibody titer between the experimental group and the control group;
[0013] Pathogen load analysis: Calculate the mean and standard deviation of pathogen load, and use the qPCR data standard curve to quantitatively analyze the pathogen load;
[0014] Clinical symptom scoring: establish clinical symptom scoring criteria, score each chicken, calculate the average symptom score of each group, and conduct statistical analysis;
[0015] Pathological analysis: The degree of synovial bursal lesions was statistically analyzed, and the differences in lesions among the groups were compared. The chi-square test was used to analyze the differences in lesion incidence.
[0016] Preferably, the method for designing the animal control group and the experimental group comprises the following steps:
[0017] S1-1. Determine the type of animal experiment and establish grouping criteria;
[0018] S1-2, design grouping method;
[0019] S1-3. Calculate the sample size.
[0020] Preferably, the S1-1, determining the type of animal experiment and establishing grouping criteria, the animal species include White Rock chicken, Riverland chicken, Rock Island Red chicken and Light-flowered Sussex chicken, and then designing the grouping criteria based on the animal species.
[0021] Preferably, the grouping criteria include weight grouping and growth cycle grouping of different types of chickens.
[0022] Preferably, the S1-2, designing a grouping method includes numbering all animals that meet the criteria, using random number generation, randomly assigning the animals to experimental groups and control groups, and then stratifying them according to body weight and growth cycle, and allocating animals within each stratum to ensure balance between groups.
[0023] Preferably, in S1-3, the sample size is calculated by using a statistical method, and the formula is:
[0024]
[0025] Where: n is the sample size required for each group, Z α / 2 is the critical value of the standard normal distribution of the significance level, Z β is the standard normal distribution critical value of the test power, σ is the population standard deviation, and Δ is the effect size, the expected difference between the experimental and control groups.
[0026] Preferably, when comparing multiple groups, a Bonferroni correction is required to take into account the problem of multiple testing:
[0027] α′=kα
[0028] Where k is the number of comparisons. At this time, the significance level becomes α′, which is used to calculate Zα′ / 2;
[0029] Considering the actual estimation of effect size and standard deviation In the actual experiment, the effect size Δ and standard deviation σ are estimated through preliminary experiments to obtain a more accurate sample size.
[0030] Preferably, the sample size calculation formula is adjusted, and the adjusted sample size calculation formula is:
[0031]
[0032] The efficacy evaluation system of the inactivated vaccine of Mycoplasma synoviae includes:
[0033] Data collection module: connects to various data collection devices, including ELISA readers, qPCR instruments, and clinical symptom recording devices, provides a data entry interface, and supports manual and automatic data entry;
[0034] Data processing module: realizes data cleaning, classification and standardization, provides data processing algorithms and tools, and supports batch data processing;
[0035] Data analysis module: integrates statistical analysis tools and algorithms, supports multiple data analysis methods, provides data visualization functions, and displays analysis results;
[0036] Effect evaluation module: integrates vaccine effectiveness and safety evaluation models, provides evaluation report generation function, and supports exporting and printing of evaluation results.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] This method and system can comprehensively evaluate the immune protection effect and safety of the vaccine, ensure the accuracy of the evaluation results through a variety of data collection and analysis methods, and the system is simple in design and easy to operate, suitable for various laboratories and field environments. It provides objective and reliable evaluation results based on scientific evaluation methods and models. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0040] Figure 1 This is a flow chart of the effect evaluation method of the inactivated vaccine of Mycoplasma synoviae of the present invention;
[0041] Figure 2 A flow chart of the method for designing the animal control group and the experimental group of the present invention;
[0042] Figure 3 This is a diagram for evaluating the effectiveness of the vaccine of the present invention;
[0043] Figure 4 It is a diagram of the effect evaluation system of the inactivated vaccine of Mycoplasma synoviae of the present invention. DETAILED DESCRIPTION
[0044] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0045] See also Figures 1 to 4 , the present invention provides a technical solution:
[0046] The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae comprises the following steps:
[0047] S1. Set up animal experimental group and control group. The experimental group will be vaccinated with inactivated vaccine, while the control group will not be vaccinated. The experimental group and control group will be divided into groups of animals of different types and production cycles. Then, animal samples will be collected, including blood, synovial fluid and tissue samples, and then clinical symptoms will be monitored.
[0048] S2. Test animal samples, measure serum antibody levels by ELISA or microneutralization test, detect pathogen load by qPCR or real-time quantitative PCR, and then observe pathological changes of synovial bursa by tissue section pathological examination;
[0049] S3. On-site data collection, including vaccination records and production performance index records. Vaccination records include vaccination dose, vaccination time, vaccination site, and production performance indicators such as weight gain, feed conversion rate, and egg production rate of laying hens;
[0050] S4. Process the data, including removing outliers and erroneous data to clean the data, classifying the data by experimental group, control group, time point, and test item, and standardizing the data to eliminate differences between different experiments;
[0051] S5. Data analysis and processing, including antibody titer analysis, pathogen load analysis, clinical symptom scoring, and pathological analysis;
[0052] S6. The effects are then evaluated, including vaccine effectiveness evaluation, comprehensive evaluation of the vaccine's immune protection effect through antibody titer, pathogen load, clinical symptom score, calculation of protection rate and relative protection rate, vaccine safety evaluation, evaluation of the incidence and severity of adverse reactions after vaccination, analysis of changes in production performance indicators, and evaluation of the impact of the vaccine on production performance.
[0053] Preferably, the antibody titer analysis: calculating the geometric mean and standard deviation of the antibody titer, and using t-test and MannWhitneyU test to compare the difference in antibody titer between the experimental group and the control group;
[0054] Pathogen load analysis: Calculate the mean and standard deviation of pathogen load, and use the qPCR data standard curve to quantitatively analyze the pathogen load;
[0055] Clinical symptom scoring: establish clinical symptom scoring criteria, score each chicken, calculate the average symptom score of each group, and conduct statistical analysis;
[0056] Pathological analysis: The degree of synovial bursal lesions was statistically analyzed, and the differences in lesions among the groups were compared. The chi-square test was used to analyze the differences in lesion incidence.
[0057] The method for designing the animal control group and the experimental group comprises the following steps:
[0058] S1-1. Determine the type of animal experiment and establish grouping criteria;
[0059] S1-2, design grouping method;
[0060] S1-3. Calculate the sample size.
[0061] Preferably, the S1-1, determining the type of animal experiment and establishing grouping criteria, the animal species include White Rock chicken, Riverland chicken, Rock Island Red chicken and Light-flowered Sussex chicken, and then designing the grouping criteria based on the animal species.
[0062] The grouping criteria include weight grouping and growth cycle grouping of different types of chickens.
[0063] The S1-2, design grouping method includes numbering all animals that meet the criteria, using random number generation, and randomly assigning the animals to experimental and control groups, and then stratifying them according to body weight and growth cycle, and allocating animals within each stratum to ensure balance between groups.
[0064] S1-3, for sample size calculation, the required sample size is calculated using statistical methods, and the formula is:
[0065]
[0066] Where: n is the sample size required for each group, Z α / 2 is the critical value of the standard normal distribution of the significance level, Z β is the standard normal distribution critical value of the test power, σ is the population standard deviation, and Δ is the effect size, the expected difference between the experimental and control groups.
[0067] When comparing multiple groups, a Bonferroni correction is required to take into account the problem of multiple testing:
[0068] α′=kα
[0069] Where k is the number of comparisons. At this time, the significance level becomes α′, which is used to calculate Zα′ / 2;
[0070] Considering the actual estimation of effect size and standard deviation In the actual experiment, the effect size Δ and standard deviation σ are estimated through preliminary experiments to obtain a more accurate sample size.
[0071] Adjust the sample size calculation formula. The adjusted sample size calculation formula is:
[0072]
[0073] The efficacy evaluation system of the inactivated vaccine of Mycoplasma synoviae includes:
[0074] Data collection module: connects to various data collection devices, including ELISA readers, qPCR instruments, and clinical symptom recording devices, provides a data entry interface, and supports manual and automatic data entry;
[0075] Data processing module: realizes data cleaning, classification and standardization, provides data processing algorithms and tools, and supports batch data processing;
[0076] Data analysis module: integrates statistical analysis tools and algorithms, supports multiple data analysis methods, provides data visualization functions, and displays analysis results;
[0077] Effect evaluation module: integrates vaccine effectiveness and safety evaluation models, provides evaluation report generation function, and supports exporting and printing of evaluation results.
[0078] System process:
[0079] Data collection: Experimenters enter and upload data through the data collection module, and the system automatically collects and stores data to ensure data integrity and security.
[0080] Data processing: The system automatically cleans, classifies and standardizes the data. The processed data is stored in the database for subsequent analysis.
[0081] Data analysis: The system performs data analysis based on preset analysis methods and models, generates analysis results and displays them in the form of charts.
[0082] Effectiveness evaluation: The system evaluates the effectiveness and safety of the vaccine based on the analysis results, generates an evaluation report, and provides expert review and verification functions.
[0083] Antibody titer assessment
[0084] Data collection: Serum samples were collected on the 7th, 14th and 21st days after vaccination.
[0085] Data analysis: Antibody titers were determined using ELISA, and the geometric mean titer and standard deviation were calculated.
[0086] Effect evaluation: Compare the antibody titer differences between the experimental group and the control group to evaluate the immune effect of the vaccine.
[0087] Pathogen load assessment
[0088] Data collection: Synovial fluid samples were collected on day 14 after inoculation.
[0089] Data analysis: The pathogen load was detected using qPCR, and the mean and standard deviation were calculated.
[0090] Effect evaluation: Compare the pathogen load between the experimental group and the control group to evaluate the inhibitory effect of the vaccine.
[0091] Clinical symptom assessment
[0092] Data collection: Record clinical symptoms within 1 week after vaccination, including fever, joint swelling, etc.
[0093] Data Analysis: Symptoms were scored and the mean symptom score for each group was calculated.
[0094] By choosing different significance levels and test powers, the sample size can be adjusted to increase the precision and confidence of the experimental results. For example:
[0095] Significance level: Lowering the significance level (e.g. from 0.05 to 0.01) will increase the required sample size. Test power: Increasing the test power (e.g. from 80% to 90%) will also increase the required sample size. Evaluation of the efficacy of chicken synoviae vaccine
[0096] Significance level: 0.05
[0097] Test efficiency: 80%
[0098] Effect size: estimated to be 5 (based on pre-experimental or literature data)
[0099] Standard deviation: estimated to be 10 (based on preliminary experiments or literature data)
[0100] calculate:
[0101]
[0102] Z β ≈0.84
[0103] σ=10
[0104] Δ=5
[0105] Sample size:
[0106] A minimum of 63 chickens are required per group.
[0107] Evaluation of the efficacy of Mycoplasma synoviae vaccine
[0108] Experimental animals: 60 chickens of the same age, weighing between 1.2kg and 1.5kg.
[0109] Grouping method:
[0110] The chickens were divided into equal groups according to body weight: 15 chickens per group.
[0111] Random allocation: Use a random number generator to assign chickens to experimental and control groups.
[0112] Experimental Group:
[0113] Experimental group A: vaccination.
[0114] Experimental group B: received high dose vaccine.
[0115] Control group:
[0116] Control group C: received placebo.
[0117] Control group D: not vaccinated.
[0118] Effect evaluation: Compare the symptom scores of the experimental group and the control group to evaluate the clinical protective effect of the vaccine
[0119] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for evaluating the effect of an inactivated vaccine of Mycoplasma synoviae, characterized in that: The steps include: S1. Set up animal experimental group and control group. The experimental group will be vaccinated with inactivated vaccine, while the control group will not be vaccinated. The experimental group and control group will be divided into groups of animals of different types and production cycles. Then, animal samples will be collected, including blood, synovial fluid and tissue samples, and then clinical symptoms will be monitored. S2. Test animal samples, measure serum antibody levels by ELISA or microneutralization test, detect pathogen load by qPCR or real-time quantitative PCR, and then observe pathological changes of synovial bursa by tissue section pathological examination; S3. On-site data collection, including vaccination records and production performance index records. Vaccination records include vaccination dose, vaccination time, vaccination site, and production performance indicators such as weight gain, feed conversion rate, and egg production rate of laying hens; S4. Process the data, including removing outliers and erroneous data to clean the data, classifying the data by experimental group, control group, time point, and test item, and standardizing the data to eliminate differences between different experiments; S5. Data analysis and processing, including antibody titer analysis, pathogen load analysis, clinical symptom scoring, and pathological analysis; S6. The effects are then evaluated, including vaccine effectiveness evaluation, comprehensive evaluation of the vaccine's immune protection effect through antibody titer, pathogen load, clinical symptom score, calculation of protection rate and relative protection rate, vaccine safety evaluation, evaluation of the incidence and severity of adverse reactions after vaccination, analysis of changes in production performance indicators, and evaluation of the impact of the vaccine on production performance.
2. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 1, characterized in that: Antibody titer analysis: Calculate the geometric mean and standard deviation of antibody titer, and use t-test and MannWhitneyU test to compare the difference in antibody titer between the experimental group and the control group; Pathogen load analysis: Calculate the mean and standard deviation of pathogen load, and use the qPCR data standard curve to quantitatively analyze the pathogen load; Clinical symptom scoring: establish clinical symptom scoring criteria, score each chicken, calculate the average symptom score of each group, and conduct statistical analysis; Pathological analysis: The degree of synovial bursal lesions was statistically analyzed, and the differences in lesions among the groups were compared. The chi-square test was used to analyze the differences in lesion incidence.
3. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 1, characterized in that: The method for designing the animal control group and the experimental group comprises the following steps: S1-1. Determine the type of animal experiment and establish grouping criteria; S1-2, design grouping method; S1-3. Calculate the sample size.
4. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 3, characterized in that: S1-1, determining the type of animal experiment and establishing grouping criteria, the animal species include White Rock chicken, Riverland chicken, Rock Island Red chicken and Light-flowered Sussex chicken, and then designing grouping criteria based on the animal species.
5. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 3, characterized in that: The grouping criteria include weight grouping and growth cycle grouping of different types of chickens.
6. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 3, characterized in that: The S1-2, design grouping method includes numbering all animals that meet the criteria, using random number generation, and randomly assigning the animals to experimental and control groups, and then stratifying them according to body weight and growth cycle, and allocating animals within each stratum to ensure balance between groups.
7. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 3, characterized in that: S1-3, for sample size calculation, the required sample size is calculated using statistical methods, and the formula is: Where: n is the sample size required for each group, Z α / 2 is the critical value of the standard normal distribution of the significance level, Z β is the standard normal distribution critical value of the test power, σ is the population standard deviation, and Δ is the effect size, the expected difference between the experimental and control groups.
8. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 7, characterized in that: When comparing multiple groups, a Bonferroni correction is required to take into account the problem of multiple testing: α′=kα Where k is the number of comparisons. At this time, the significance level becomes α′, which is used to calculate Zα′ / 2; Considering the actual estimation of effect size and standard deviation In the actual experiment, the effect size Δ and standard deviation σ are estimated through preliminary experiments to obtain a more accurate sample size.
9. The method for evaluating the effect of the inactivated vaccine of Mycoplasma synoviae according to claim 8, characterized in that: Adjust the sample size calculation formula. The adjusted sample size calculation formula is:
10. The effect evaluation system of the inactivated Mycoplasma synoviae vaccine according to any one of claims 1 to 9, characterized in that: include: Data collection module: connects to various data collection devices, including ELISA readers, qPCR instruments, and clinical symptom recording devices, provides a data entry interface, and supports manual and automatic data entry; Data processing module: realizes data cleaning, classification and standardization, provides data processing algorithms and tools, and supports batch data processing; Data analysis module: integrates statistical analysis tools and algorithms, supports multiple data analysis methods, provides data visualization functions, and displays analysis results; Effect evaluation module: integrates vaccine effectiveness and safety evaluation models, provides evaluation report generation function, and supports exporting and printing of evaluation results.
